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Brain grey matter volume 
alterations associated with 
antidepressant response in major 
depressive disorder
Jia Liu1, Xin Xu2, Qiang Luo1, Ya Luo2, Ying Chen2, Su Lui1, Min Wu1, Hongyan Zhu3,  
Graham J. Kemp4,5 & Qiyong Gong1
Not all patients with major depressive disorder respond to adequate pharmacological therapy. 
Psychoradiological studies have reported that antidepressant responders and nonresponders show 
different alterations in brain grey matter, but the findings are inconsistent. The present study reports 
a meta-analysis of voxel-based morphometric studies of patients with major depressive disorder, both 
antidepressant responders and nonresponders, using the anisotropic effect size version of Seed-based 
D Mapping to identify brain regions correlated to clinical response. A systematic search was conducted 
up to June 2016 to identify studies focussing on antidepressant response. In responders across 9 
datasets grey matter volume (GMV) was significantly higher in the left inferior frontal gyrus and insula, 
while GMV was significantly lower in the bilateral anterior cingulate cortex (ACC) and the right superior 
frontal gyrus (SFG). In nonresponders across 5 datasets GMV was significantly lower in the bilateral ACC, 
median cingulate cortex (MCC) and right SFG. Conjunction analysis confirmed significant differences 
in the bilateral ACC and right SFG, where GMV was significantly lower in nonresponders but higher in 
responders. The current study adds to psychoradiology, an evolving subspecialty of radiology mainly 
for psychiatry and clinical psychology.
Major depressive disorder (MDD) accounts for a large burden of disease, and is a leading cause of years lived with 
disability1. Antidepressant medication is a first-line treatment for severe MDD2, and has been shown to amelio-
rate functional impairment, with changes in neural activation and brain structure3, 4. However, ~30% of patients 
do not respond to adequate pharmacological therapy, and the pathophysiological mechanisms linking depression, 
structural change and treatment response remain unclear5–7.
Although antidepressant responders and nonresponders show grey matter volume (GMV) alterations by 
structural magnetic resonance imaging (MRI)8–10, reports relating to antidepressant effects are inconsistent. For 
example, higher GMV in the right superior temporal gyrus was reported in one study of responders11, while 
lower GMV in the right superior frontal gyrus of nonresponders has been observed in some studies8, 9, 12, but 
not others13. Variations in sample sizes, imaging protocols, and the demographic and clinical characteristics of 
the patients may underlie much of this inconsistency. Meta-analysis therefore offers a valuable way to define 
consistent GMV abnormalities in MDD responders and nonresponders, to throw light on the pathophysiological 
mechanisms underlying antidepressant effects.
The automated analysis method of voxel-based morphometry (VBM) provides a powerful tool to compare 
group differences in GMV at whole-brain level14. To identify consistent regional GMV abnormalities in relation 
to antidepressant effect, both positive and negative results of VBM studies can be combined in the same map 
by using a particular voxel-based meta-analytic approach, the Anisotropic Effect Size version of Seed-based D 
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Mapping (http://www.sdmproject.com, AES-SDM). AES-SDM supports effect size comparison and conjunction 
analysis15, and has been used to compare MDD with bipolar disorder16, 17 and in other neurologic disorders such 
as migraine18 and dementia19.
Using AES-SDM, this systematic meta-analysis aimed to (1) investigate morphometric changes in MDD 
responders and nonresponders compared with healthy controls, and (2) compare GMV differences that may 
define specific and shared morphological alterations in responders and nonresponders.
Results
Included studies and their characteristics. We found 2512 studies, of which 10 studies4, 8, 9, 11–13, 20–23 
ultimately met the inclusion criteria. No additional study was identified from their references. Figure S1 shows a 
flow diagram of study selection. This left a total of 10 articles for our meta-analysis, with responders across 9 data-
sets (199 patients vs. 308 controls) and nonresponders across 5 datasets (120 patients vs. 132 controls). Table 1 
summarises the clinical characteristics of these groups in the various studies.
Antidepressant responders and nonresponders vs. healthy controls. Table 2 and Fig. 1 show the 
results of meta-analysis of both patient groups against healthy controls.
Group comparison of responders against healthy controls revealed higher GMV in the bilateral anterior cin-
gulate cortex (ACC), the right superior frontal gyrus (SFG) and gyrus rectus, and lower GMV mainly in the left 
inferior frontal gyrus (IFG) and insula. Results from subgroup analysis were consistent with these results.
Group comparison of nonresponders against healthy controls revealed lower GMV in the bilateral median 
cingulate cortex (MCC), ACC, and right SFG. There was no higher GMV in the nonresponders.
Antidepressant nonresponders vs. responders. Conjunction analysis found significant differences in 
the bilateral ACC and right SFG, where GMV was lower in nonresponders but higher in responders.
Jack-knife sensitivity analysis. Tables 3 and 4 show the results of whole-brain jack-knife sensitivity analy-
sis. In responders, higher GMV in the right SFG and lower GMV in the left IFG and insula were highly replicable, 
being preserved throughout all 9 combinations of the datasets; higher GMV in the bilateral ACC and right gyrus 
rectus were significant in all but 1 combination. In nonresponders, lower GMV in bilateral MCC, ACC and right 
SFG were significant in all but 1 combination of the data sets.
Meta-regression analysis and publication bias analysis. We conducted meta-regression analyses to 
explore the association between GMV alteration and clinical data including the mean age, illness duration and 
the percentage of female patients in responders. Only GMV in the left insula showed positive correlation with 
illness duration (Fig. 2, peak MNI = −32, 16, 2 Z = 1.234, P = 0.0038, 113 voxels). However, this result should 
be interpreted with caution as it is driven by only three studies, and variability across studies might affect this 
Studies
Number (female) Mean age, y Severity (scale type) Illness duration 
(months)
Scan 
time Antidepressants MRI
Quality 
scoreMDD HC MDD HC Pre-tx Pre-tx
Responders
Fang et al.11 20 (8) 18(8) 59.2 (3.7) 59.1 (7.5) 26.6(1.9) (HDRS) 6.4(0.98) (HDRS) 43.2(13.2) Post-tx Unclear 1.5 T 12
Jung et al.12 24 (17) 29(21) 43.0 (10.1) 43.6 (13.4) 20.9(4.1) (HDRS) 7.3(2.6) (HDRS) 33.3(43.1) Pre-tx SSRI/SNRI/others* 3 T 12.5
Klauser et al.5 27 (18) 33(21) 35.0 (9.72) 34.7 (9.93) NA 13.04(11.73) (BDI) 108.48(78.36) Post-tx SSRI/SNRI/others 1.5 T 12
Kong et al.20 24 (14) 28(14) 36.1 (5.73) 32.1 (9.27) NA 3.42(2.55) (HDRS) 4.12(0.89) Post-tx Fluoxetine 1.5 T 12.5
Li et al.13 19 (13) 25(19) 42.6 (13.0) 40.6 (12.7) 21.0(4.0) (HDRS) 3.4(2.0) (HDRS) 108(78.36) Pre-tx SSRI/SNRI/others 1.5 T 12
Liu et al.22 19 (19) 19(19) 37.6 (12.7) 36.8 (11.2) NA 4.63 (HDRS) 88.44(66.4) Post-tx SSRI/SNRI/others 3 T 11.5
Ma. et al.21 17 (7) 17(7) 26.7 (7.73) 24.2 (4.41) 25.58(6.32) (HDRS) NA 2.59(1.33) Pre-tx SSRI/SNRI/TCA 1.5 T 11
Salvadore et al.23 27 (21) 107(60) 40.2 (12.2) 36.2 (0.3) NA 1.6(2.3) (MADRS) 181.2(164.4) Post-tx Unclear 3 T 12
Serra-Blasco et al.9 22 (20) 32(23) 48.0 (8.7) 46.0 (8.3) NA 4(5.2) (HDRS) 214.3(129) Post-tx SSRI/SNRI/others 3 T 12
Nonresponders
Jung et al.12 26 (19) 29(21) 40.8 (12.7) 43.6 (13.4) 18.8(4.7) (HDRS) 14.9(4.6) (HDRS) 36.4(33.2) Pre-tx SSRI/SNRI/others 3 T 12.5
Li et al.13 25 (20) 25(19) 46.5 (10.4) 40.6 (12.7) 21.9(3.5) (HDRS) 16.3(6.0) (HDRS) 112.8(102) Pre-tx SSRI/SNRI/ others 1.5 T 12
Ma. et al.21 18 (7) 17(7) 27.4 (7.74) 24.2 (4.41) 23.89(3.69) (HDRS) NA 35.5(49.89) Pre-tx SSRI/SNRI/TCA 1.5 T 11
Machino et al.8 29 (13) 29(13) 39.6 (8.29) 38.7 (8.36) NA 13.9(4.33) (HDRS) 52.55 Post-tx SSRI/SNRI/ others 1.5 T 11
Serra-Blasco et al.9 22 (18) 32(23) 49.0 (8) 46.0 (8.3) NA 21(4.6) (HDRS) 271 Post-tx SSRI/SNRI/others 3 T 12
Table 1. Characteristics of patient and control groups in studies included in the meta-analysis. BDI = Beck 
Depression Inventory; HC = healthy controls; HDRS = 17-item Hamilton Depression Rating Scale; 
m = months; MADRS = Montgomery and Åsberg Depression Rating Scale; MAOI = monoamine oxidase 
inhibitors; NaSSA = noradrenergic/specific serotonergic agents; NDRI = norepinephrine dopamine reuptake 
inhibitor; Pre-tx = pre-treatment; Post-tx = post-treatment; SSRI = specific serotonin reuptake inhibitors; 
SNRI = serotonin norepinephrine reuptake inhibitors; TCA = tricyclic antidepressants; y = years; *others 
including TCA, NDRI, NaSSA and MAOI; All data are given as the mean (SD) if not otherwise specified.
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Brain Regions
Maximum Clusters
MNI coordinates, x,y,z SDM value p-value No. of voxels Breakdown (no. of voxels)
Responders > HC
Right frontal orbito-polar tract 18, 30, −18 2.321 0.000055730 411 R superior frontal gyrus, orbital part, BA 11 (157)
R gyrus rectus, BA 11 (112)
R frontal orbito-polar tract (93)
R inferior frontal gyrus, orbital part, BA 11 (49)
Corpus callosum 6,34,2 2.221 0.000240505 333 R anterior cingulate cortex, BA 10,11,24,25,32 (152)
L anterior cingulate cortex, BA 10,11,24,25,32 (131)
Corpus callosum (50)
Responders < HC
L insula, BA 48 −32,16,8 −1.658 0.000001013 909 L insula, BA 45,47 (451)
L inferior frontal gyrus, BA 44,45,47,48 (262)
L superior longitudinal fasciculus III (100)
Left temporal pole, superior temporal gyrus, BA 
48 (50)
Left frontal aslant tract (23)
Left lenticular nucleus, putamen, BA 48 (23)
Left inferior frontal gyrus, BA 48 −36,14,26 −1.019 0.001406848 42 L inferior frontal gyrus, BA 44,48 (42)
L frontal inferior longitudinal fasciculus (15)
Subgroup analysis
Responders post-tx > HC
Right superior frontal gyrus, BA 11 20,30,−16 2.287 0.000110447 345 R superior frontal gyrus, orbital part, BA 11,25 (149)
R gyrus rectus, BA 11 (82)
R frontal orbito-polar tract (64)
R inferior frontal gyrus, orbital part, BA 11 (50)
Corpus callosum −4,34,2 2.280 0.000156879 265 R anterior cingulate cortex, BA 10,11,24,25,32 (106)
L anterior cingulate cortex, BA 10,11,24,25,32 (107)
Corpus callosum (52)
Responders post-tx < HC
Left superior longitudinal fasciculus III −34,20,12 −1.566 0.000009298 L insula, BA 45,47(144)
L inferior frontal gyrus, BA 44,45,47,48 (140)
L superior longitudinal fasciculus III (75)
Left frontal inferior longitudinal fasciculus −36,20,22 −1.138 0.000341654 L inferior frontal gyrus, BA 44,48 (55)
Left frontal inferior longitudinal fasciculus (23)
Nonresponders > HC — — — — —
Nonresponders < HC
Corpus callosum 6,6,28 −2.246 0.000132143 572 R median cingulate cortex, BA 24,23 (146)
L median cingulate cortex, BA 24,23 (128)
L anterior cingulate cortex, BA 24 (97)
Corpus callosum (87)
Left median network, cingulum (65)
R anterior cingulate cortex, BA 24 (49)
R superior frontal gyrus, BA 9 16,38,46 −1.899 0.000587285 152 R superior frontal gyrus, BA 8,9 (122)
Corpus callosum (30)
Right superior frontal gyrus, medial, BA 10 2,48,2 −1.742 0.001101315 87 L anterior cingulate cortex, BA 10,32 (52)
R superior frontal gyrus, medial, BA 10 (23)
R anterior cingulate cortex, BA 10,32 (12)
Responders > Nonresponders
R anterior cingulate/paracingulate gyri 2,42,0 2.857 <0.001 283
L anterior cingulate/paracingulate gyri 0,30,20 1.165 <0.001 43
R superior frontal gyrus 4,58,4 2.024 <0.001 744
Responders < Nonresponders
— — — — —
Table 2. Regional differences in grey matter volume in antidepressant responders and nonresponders compared 
with healthy controls BA = Brodmann area; HC = healthy controls; L = left; M = middle; MNI = Montreal 
Neurological Institute; Post-tx = post-treatment; R = right; SDM = signed differential mapping.
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analysis. Egger’s test of funnel plots in the responders (Figure S2) reveals asymmetry for the left insula (p = 0.105) 
and IFG (p = 0.534).
Discussion
This meta-analysis is the first to analyze VBM studies in MDD antidepressant responders and nonresponders 
compared with healthy controls. GMV alterations in the cortico-limbic circuit, especially the prefrontal regions 
and ACC, were observed in both patient groups, implicating this in the intrinsic pathophysiology of major 
depressive disorder. However, there were notable differences between the patient groups. GMV in the bilateral 
ACC and right SFG was higher in responders, but lower in nonresponders. Lower GMV in the left insula and 
inferior frontal gyrus and higher GMV in right gyrus rectus were only observed in responders, and lower GMV 
in bilateral MCC was only observed in nonresponders, suggesting links to different mechanisms.
Generally, only responders showed higher GMV compared with healthy controls, while nonresponders 
showed broadly lower GMV. Previous neuroimaging studies have reported lower GMV in MDD17, 24, and post-
mortem studies have, accordingly, shown decreases in the density, number and size of neuronal and glial cells25, 26. 
Antidepressant drugs may restore GMV in responsive patients27, possibly through synaptic plasticity and altered 
expression of neurotrophic factors28, 29. This may explain why responders showed higher GMV while nonre-
sponders showed lower GMV.
We found GMV differences in the bilateral ACC and right SFG, which were higher in responders but lower 
in nonresponders. This is consistent with reports that GMV is lower in SFG and that this correlates with the 
severity of depression30, 31 and that remission of depressive symptoms is associated with higher GMV in right 
ACC32–34, higher functional and metabolic activity in ACC35–37 and altered connectivity of the cingulate tracts38. 
As the major regions in the cortical-limbic network, bilateral ACC and right SFG are involved in dysfunctional 
mood and emotional regulation in MDD39, 40. Given that antidepressant medication influences brain structure 
mainly through the serotonergic system41, 42, GMV in bilateral ACC and right SFG might be especially sensitive 
to the clinical response to pharmacotherapy. Interestingly, a PET study found that nonresponders had lower 
serotonin transporter binding in ACC than responders43. A previous meta-analysis found the most robust 
grey matter reductions in a relatively focal region in rostral ACC, both in the pooled meta-analysis and in the 
subgroup analysis of multi-episode samples44, but not in subgroup analysis of first-episode studies44. A recent 
meta-analysis in first-episode depression also failed to find lower grey matter volume in the ACC45. As the symp-
toms of first-episode patients (and in our study, responders) are relatively lighter, this might suggest that ACC 
abnormalities are sensitive to the severity of symptoms in depressed patients.
In responders, GMV was lower in the left insula and IFG. Consistent with this are previous reports that lower 
GMV in bilateral insula is correlated with severity of depression46, and that GMV is lower in the left insula in 
current and remitted MDD47. Functional neuroimaging studies in MDD patients have implicated the insular 
cortex in the emotional processing of guilt and sadness48, 49. The lower GMV in the left insula in our study appears 
consistent with functional studies in MDD demonstrating lower activity in the bilateral or left-side insula50, 51. 
Although the role of the insula in the pathophysiological processing in MDD still need be clarified, our results sug-
gest a positive involvement in the treatment response of MDD patients, as was also observed in medication-free 
MDD patients in a previous meta-analysis52. Furthermore, meta-analysis of studies of medication-free patients 
with MDD has also shown lower GMV in the IFG52. In a longitudinal functional neuroimaging study using near 
infrared spectroscopy (NIRS), both untreated and remitted MDD groups showed significantly lower [oxy-Hb] 
activation during a verbal fluency task in the bilateral prefrontal cortices compared to HC53. These findings may 
indicate that brain structure and function in the left insula and IFG remains impaired in remitted patients even 
after improvement of depressive symptoms.
The study has some limitations. First, the generalizability of the results was limited by the small sample size 
which combined only 5 nonresponder datasets and 9 responder datasets, which also meant that meta-regression 
could not be performed on the nonresponders. Second, important variables like intelligence quotient and hand-
edness were not generally reported, precluding exploration of their impact on the results. Third, there is the 
potential for bias in the VBM method, whose relative insensitivity to spatially more diverse changes can lead to 
over-representation of group differences in regions of high anatomic variability. Fourth, the number of included 
studies was insufficient for an analysis of the effects of particular antidepressants or antidepressant classes. Fifth is 
the imprecision inherent in all methods depending on summarized coordinates, which are nevertheless necessary 
because published studies typically use different covariate models or raw statistics.
Conclusion
Taken together, the present findings demonstrate structural grey matter differences in regions involved in 
cortico-limbic networks in MDD patients. GMV of the bilateral ACC and right SFG was lower in nonrespond-
ers, but higher in the responders, suggesting that this might provide biomarkers associated with antidepressant 
response and prolonged remission. Furthermore, lower GMV in the left insula and IFG was only present in 
responders. Longitudinal studies will need to investigate the dynamic effect of antidepressant medication, and 
for a better understanding of the underlying cause of these GMV alterations. In particular, this study adds to 
Psychoradiology (https://radiopaedia.org/articles/psychoradiology), an evolving subspecialty of radiology, which 
is primed to play a major clinical role in guiding diagnostic and therapeutic decisions in patients with mental 
disorders54, 55.
Methods
Inclusion criteria. We followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses 
guidelines (PRISMA)56. We searched for recent studies published in Pubmed, Embase and Web of Science up 
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to June 2016, using the keywords ‘depressive disorder’ or ‘unipolar depression’ or ‘depression’ or ‘depress*’ plus 
‘VBM’ or ‘voxel-based morphometry’ or ‘voxel’ or ‘morphometry’. We also checked the reference lists of those 
articles for further researches.
Studies were included according to the following criteria: (1) a group of participants diagnosed as having 
MDD based on DSM criteria were compared with healthy controls; (2) VBM was used to analyze grey matter 
alteration in MDD patients; (3) coordinates were reported in a standard space like the Talairach space or the 
Montreal Neurological Institute (MNI) space; (4) the nonresponder group was defined as showing < 50% reduc-
tion in the 17-item Hamilton Depression Rating Scale (HDRS-17) total score (or Beck Depression Inventory or 
Montgomery and Åsberg Depression Rating Scale), and the responder group was defined as ≥50% reduction in 
the same scale, after treatment at a sufficient dose for 6 weeks.
Studies were excluded if they met the following criteria: (1) MDD patients were not compared with healthy 
controls; (2) coordinates were not clearly reported; (3) VBM was not used; (4) comorbid panic disorder was not 
excluded; (5) late-onset MDD patients or adolescents with MDD were enrolled.
Study selection. Two investigators independently examined abstracts from the initial search, and disagree-
ments were discussed with a third author to reach a consensus. Authors were blinded to the articles’ authors, their 
Figure 1. Regional differences in grey matter volume in antidepressant responders and nonresponders vs. 
healthy controls and antidepressant nonresponders vs. responders by meta-analysis. The figure shows areas 
of lower (blue) and higher (red) grey matter volumes in (A) responders and (B) nonresponders compared 
with healthy controls, and nonresponders compared with responders (C). Abbreviation: ACC = anterior 
cingulate cortex; B = bilateral; IFG = inferior frontal gyrus; L = left; MCC = median cingulate cortex; R = right; 
SFG = superior frontal gyrus.
www.nature.com/scientificreports/
6SCIentIFIC REPORtS | 7: 10464  | DOI:10.1038/s41598-017-10676-5
institutions and the source of funding in order to minimize potential bias. The full texts of studies thought to 
fulfill the inclusion criteria were assessed in detail to confirm eligibility.
Data extraction. Two authors independently extracted data. Differences were resolved by discussion among 
the review authors. The following data were collected: first author’s name, year of publication, details of study 
design, patient characteristics (including gender, age, illness duration, and disease severity at baseline), sample 
size, agent dose, duration of treatment and changes in VBM. From each included study we chose the statistically 
significant peak coordinates of GMV differences resulting from whole brain analysis.
Studies
Higher grey matter Lower grey matter
R SFG R GR R IFG R ACC L ACC L IFG L insula
Fang, J. et al.10 Y Y Y Y Y Y Y
Jung, J. et al.11 Y Y Y Y Y Y Y
Klauser P. et al.4 Y Y Y Y Y Y Y
Kong, L. et al.19 Y Y Y Y Y Y Y
Li, C.T. et al.12 Y Y Y Y Y Y Y
Liu, et al.21 Y Y Y Y Y Y Y
Ma C. et al.20 Y Y Y Y Y Y Y
Salvadore, G. et al.22 Y N N N N Y Y
Serra-Blasco, M. et al.9 Y Y Y Y Y Y Y
Table 3. Sensitivity analyses of voxel-based morphometric studies of grey matter in antidepressant responders 
compared with healthy controls. ACC = anterior cingulate cortex; GR = gyrus rectus; IFG = inferior frontal 
gyrus; L = left; r = right; SFG = superior frontal gyrus.
Studies
Lower grey matter
L MCC L ACC R MCC R ACC R SFG
Jung, J. et al.11 Y Y Y Y Y
Li, C. et al.12 Y Y Y Y Y
Ma C et al.20 Y Y Y Y Y
Machino, A. et al.8 N N N N N
Serra-Blasco, M. et al.9 Y Y Y Y Y
Table 4. Sensitivity analyses of voxel-based morphometric studies of grey matter in antidepressant 
nonresponders compared with healthy controls. ACC = anterior cingulate cortex; HG = Heschl gyrus; 
IFG = inferior frontal gyrus; L = left; LG = lingual gyrus; MCC = median cingulate cortex; SFG = superior 
frontal gyrus.
Figure 2. Association of grey matter volume in insula with illness duration in antidepressant responders 
compared with healthy controls, by meta-regression analysis.
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Quality assessment. Based on previous studies35, 57, 58, the included studies were assessed for quality using a 
13-point checklist, including clinical and demographic aspects as well as the imaging methodology. Two authors 
independently reviewed each paper and assigned a completeness rating for the following items: the quality of 
the diagnostic procedures, the demographic and clinical characterization, the sample size, the MRI acquisi-
tion parameters, the analysis technique and the quality of the reported results (see the Supplement, Table S1). 
Differences were resolved by discussion among the review authors and a consensus score was assigned, as pre-
sented in Table 1.
Statistical Analysis. First, independent voxel-wise effects meta-analyses were conducted to investigate 
regional GMV differences within both responsive and non-responsive groups relative to controls. Second, sub-
group analysis in responsive group was performed to investigate the GMV change after antidepressant treatment. 
Third, conjunction analysis was conducted to identify distinct brain regions where non-responders and respond-
ers differed from healthy controls; this used a multimodal analysis to compare the results from two independ-
ent meta-analysis17, 59. The AES-SDM method has been described in detail elsewhere15, and we only describe it 
briefly here. First, the peak coordinates of the brain regions that were significantly different at the whole-brain 
level were selected. To avoid a potential bias toward liberally thresholded regions, we checked all the included 
studies to ensure that the same threshold was used throughout the brain. Second, we separately recreated a stand-
ard Talairach map of the differences in grey matter for each study by using a Gaussian kernel. The recreation 
of the peak coordinates was based on converting the peak t value to Hedges’ effect size, and then applying a 
non-normalized Gaussian kernel to the voxels near the peak, which assigns higher values to the voxels closer to 
peaks. For null findings in the studies, the recreation was done with the same effect size, and all voxels in the effect 
size map were estimated to have a null effect size, which was the only difference. Similar to other effect sizes, the 
null effect size was also included in the random-effects meta-analytic models, thus modifying the meta-analytic 
effect size. Third, the mean of the study maps were analyzed using a voxel-wise calculation to generate a mean 
map, and this calculation was weighted by the square root of the sample size of each study, so a study with a larger 
sample size would contribute more. Finally, we used standard randomization tests to determine statistical signifi-
cance, hence creating null distributions from which p values were directly obtained. The default AES-SDM kernel 
size and thresholds were used (full-width at half-maximum = 20 mm, voxel p = 0.005, peak height Z = 1, cluster 
extent = 10 voxels).
Reliability analysis. The reliability of results was examined by using Jack-knife sensitivity analysis. The sen-
sitivity analysis was repeated 5 times for nonresponder groups and 9 times for responder groups, to find highly 
replicable brain regions which were preserved throughout most combinations of the datasets.
Meta-regression analysis and publication bias analysis. Meta-regression was used to explore 
which of the following moderator variables might be responsible for heterogeneity of the findings: mean age of 
patients, illness duration, and the percentage of female patients. In the absence of consistent depression-scale 
data, meta-regression to depression symptom severity was not feasible. The probability threshold was reduced to 
0.0005 to decrease the finding of spurious associations as less as possible, and regions which are not in the main 
analysis were ignored. Effect size estimates of the significant clusters were extracted to examine publication bias 
by using Egger’s test and funnel plots.
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